SpringWorks Shares Rise on FDA Approval for Tumor Treatment
By Dean Seal
Shares of SpringWorks were higher after the company received regulatory approval for its treatment of desmoid tumors.
The stock was up 11% at $23.01 in premarket trading. Shares had fallen 20% year-to-date when the market closed Monday.
The Stamford, Conn.-based biopharmaceutical company said after the bell on Monday that the U.S. Food and Drug Administration has approved Ogsiveo for adults with progressing desmoid tumors who require systemic treatment.
SpringWorks said Ogsiveo was the first FDA-approved therapy for patients with desmoid tumors.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 28, 2023 07:38 ET (12:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
What’s Happening In the Markets This Week
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase
-
After Earnings, Is Nio Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Lululemon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks